David A. Siegel Intellia Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,982,317 shares of NTLA stock, worth $18.2 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,982,317

Previous 1,998,317 0.8%

Holding current value

$18.2 Million

Previous $23.3 Million 39.51%

% of portfolio

0.03%

Previous 0.06%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$7.11 - $12.8 $113,760 - $204,800	-16,000 Reduced 0.8%	1,982,317 $14.1 Million
Q4 2024 Feb 14, 2025	BUY	$11.41 - $21.09 $11.1 Million - $20.5 Million	970,700 Added 94.46%	1,998,317 $23.3 Million
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $5.08 Million - $7.05 Million	257,700 Added 33.47%	1,027,617 $21.1 Million
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $2.21 Million - $3.01 Million	110,600 Added 16.77%	769,917 $17.2 Million
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $4.65 Million - $6.41 Million	195,300 Added 42.09%	659,317 $18.1 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $4.87 Million - $6.8 Million	210,400 Added 82.96%	464,017 $14.1 Million
Q3 2023 Nov 14, 2023	SELL	$31.62 - $45.78 $777,852 - $1.13 Million	-24,600 Reduced 8.84%	253,617 $8.02 Million
Q2 2023 Aug 14, 2023	SELL	$34.58 - $46.03 $8.91 Million - $11.9 Million	-257,700 Reduced 48.09%	278,217 $11.3 Million
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $1.54 Million - $2.08 Million	-46,300 Reduced 7.95%	535,917 $20 Million
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $56,457 - $106,573	-1,700 Reduced 0.29%	582,217 $20.3 Million
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $7.08 Million - $9.41 Million	-131,300 Reduced 18.36%	583,917 $32.7 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $10.7 Million - $21.1 Million	277,200 Added 63.29%	715,217 $37 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $9.75 Million - $19.9 Million	167,300 Added 61.8%	438,017 $31.8 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $10.2 Million - $13.9 Million	100,800 Added 59.32%	270,717 $32 Million
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $31.8 Million - $42.5 Million	-240,300 Reduced 58.58%	169,917 $22.8 Million
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $16.4 Million - $43.6 Million	-269,500 Reduced 39.65%	410,217 $66.4 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $6.49 Million - $11.6 Million	139,200 Added 25.75%	679,717 $54.6 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $1.58 Million - $5.33 Million	83,900 Added 18.37%	540,517 $29.4 Million
Q3 2020 Nov 16, 2020	BUY	$17.47 - $24.93 $2.22 Million - $3.17 Million	127,300 Added 38.66%	456,617 $9.08 Million
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $806,536 - $1.66 Million	72,400 Added 28.18%	329,317 $6.92 Million
Q1 2020 May 15, 2020	BUY	$9.44 - $15.58 $236,000 - $389,500	25,000 Added 10.78%	256,917 $3.14 Million
Q4 2019 Feb 14, 2020	BUY	$10.43 - $17.67 $975,205 - $1.65 Million	93,500 Added 67.55%	231,917 $3.4 Million
Q3 2019 Nov 14, 2019	BUY	$13.07 - $18.51 $533,256 - $755,208	40,800 Added 41.8%	138,417 $1.85 Million
Q2 2019 Aug 14, 2019	BUY	$13.88 - $18.41 $861,948 - $1.14 Million	62,100 Added 174.85%	97,617 $1.6 Million
Q1 2019 May 15, 2019	BUY	$12.79 - $17.62 $184,176 - $253,728	14,400 Added 68.19%	35,517 $607,000
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $240,522 - $572,904	21,117 New	21,117 $288,000

Others Institutions Holding NTLA

# of Institutions

344

Shares Held

98.4M

Call Options Held

784K

Put Options Held

713K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $699M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account